GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enanta Pharmaceuticals Inc (NAS:ENTA) » Definitions » Cyclically Adjusted Book per Share

Enanta Pharmaceuticals (Enanta Pharmaceuticals) Cyclically Adjusted Book per Share : $19.68 (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Enanta Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Enanta Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2024 was $7.843. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $19.68 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Enanta Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 4.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-09), Enanta Pharmaceuticals's current stock price is $12.91. Enanta Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $19.68. Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.66.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Enanta Pharmaceuticals was 6.72. The lowest was 0.43. And the median was 2.81.


Enanta Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Enanta Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enanta Pharmaceuticals Cyclically Adjusted Book per Share Chart

Enanta Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 14.48 18.20 19.35

Enanta Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.85 19.12 19.35 19.31 19.68

Competitive Comparison of Enanta Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Enanta Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Enanta Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=7.843/131.7762*131.7762
=7.843

Current CPI (Mar. 2024) = 131.7762.

Enanta Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 8.232 100.560 10.787
201409 7.994 100.428 10.489
201412 10.407 99.070 13.843
201503 11.996 99.621 15.868
201506 12.202 100.684 15.970
201509 12.617 100.392 16.561
201512 14.061 99.792 18.568
201603 14.054 100.470 18.433
201606 14.132 101.688 18.313
201609 14.180 101.861 18.344
201612 14.084 101.863 18.220
201703 13.961 102.862 17.885
201706 13.665 103.349 17.424
201709 15.778 104.136 19.966
201712 16.584 104.011 21.011
201803 17.311 105.290 21.666
201806 18.642 106.317 23.106
201809 20.298 106.507 25.114
201812 21.962 105.998 27.303
201903 22.178 107.251 27.250
201906 22.767 108.070 27.761
201909 23.473 108.329 28.553
201912 24.346 108.420 29.591
202003 24.317 108.902 29.425
202006 23.944 108.767 29.009
202009 22.692 109.815 27.230
202012 22.440 109.897 26.908
202103 21.602 111.754 25.472
202106 20.674 114.631 23.766
202109 19.737 115.734 22.473
202112 18.745 117.630 20.999
202203 17.392 121.301 18.894
202206 16.313 125.017 17.195
202209 15.455 125.227 16.263
202212 14.405 125.222 15.159
202303 12.798 127.348 13.243
202306 11.295 128.729 11.562
202309 10.292 129.860 10.444
202312 9.070 129.419 9.235
202403 7.843 131.776 7.843

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Enanta Pharmaceuticals  (NAS:ENTA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=12.91/19.68
=0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Enanta Pharmaceuticals was 6.72. The lowest was 0.43. And the median was 2.81.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Enanta Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Enanta Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Enanta Pharmaceuticals (Enanta Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
500 Arsenal Street, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Executives
Terry Vance director C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Scott T. Rottinghaus officer: Chief Medical Officer C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Brendan Luu officer: Sr. VP, Business Dev. C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Tara Lynn Kieffer officer: Sr. VP, New Product Dev. C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Yat Sun Or officer: Chief Scientific Officer C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Jay R. Luly director, officer: President and CEO C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Nathaniel S. Gardiner director C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Paul J Mellett officer: Treasurer and CFO C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Nathalie Adda officer: Sr. VP & Chief Medical Officer C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Carter Bruce L A director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102
Lesley Russell director 41 MOORES RD., FRAZER PA 19355
Yujiro S Hata director C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Mark G Foletta director AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121
Kristine Peterson director AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901

Enanta Pharmaceuticals (Enanta Pharmaceuticals) Headlines

From GuruFocus